Scholarlink

Background and Purpose <p>Delirium and encephalopathy are frequent causes of hospitalization leading to functional disability and cognitive impairment. Recent studies have suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may protect against neurodegeneration in conditions such as Alzheimer's dementia and Parkinson’s disease. However, there is limited literature on their benefits in delirium and encephalopathy. This scoping review explores the mechanisms of GLP-1 RAs in relation to delirium and encephalopathy based on animal studies, and presents current clinical evidence on their potential benefits for managing these neurological disorders.</p> Methodology <p>A literature search was conducted on PubMed, Embase, Google Scholar,Web of Science, and APA PsycInfo using search terms related to GLP-1 RAs, delirium, and encephalopathy, in which GLP-1 RAs may have potential benefits. In accordance with the Prisma-Scr guidelines, a total of 38 articles were included in the scoping review.</p> Results <p>This review focuses on several key brain dysfunctions in which GLP-1 RAs may offer potential benefits. These include postoperative delirium, sepsis-associated encephalopathy, hepatic encephalopathy, hypoxia-induced encephalopathy, diabetic encephalopathy, and alcohol withdrawal syndrome. Both preclinical and clinical studies suggest that GLP-1 RAs may provide neuroprotective benefits, including anti-apoptotic, anti-inflammatory, and cognitive-enhancing properties. These neuroprotective effects are supported by the molecular and pathophysiological pathways that could serve as potential targets for GLP-1 RAs.</p> Conclusion <p>GLP-1 RAs may offer neuroprotective benefits in patients with postoperative delirium and encephalopathies.. Cellular benefits involve pathophysiological or molecular pathways that are shared with other biological systems. While the current evidence is based on preclinical and clinical studies, more research involving human subjects is needed to clarify the role of GLP-1 RAs in various brain dysfunctions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GLP-1 receptor agonists in delirium and encephalopathies: a neuroprotective scoping review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月31日

查看全文
  • Francisco Mercado,
  • Michaela Kop,
  • Michelle Trinh

摘要

Background and Purpose

Delirium and encephalopathy are frequent causes of hospitalization leading to functional disability and cognitive impairment. Recent studies have suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may protect against neurodegeneration in conditions such as Alzheimer's dementia and Parkinson’s disease. However, there is limited literature on their benefits in delirium and encephalopathy. This scoping review explores the mechanisms of GLP-1 RAs in relation to delirium and encephalopathy based on animal studies, and presents current clinical evidence on their potential benefits for managing these neurological disorders.

Methodology

A literature search was conducted on PubMed, Embase, Google Scholar,Web of Science, and APA PsycInfo using search terms related to GLP-1 RAs, delirium, and encephalopathy, in which GLP-1 RAs may have potential benefits. In accordance with the Prisma-Scr guidelines, a total of 38 articles were included in the scoping review.

Results

This review focuses on several key brain dysfunctions in which GLP-1 RAs may offer potential benefits. These include postoperative delirium, sepsis-associated encephalopathy, hepatic encephalopathy, hypoxia-induced encephalopathy, diabetic encephalopathy, and alcohol withdrawal syndrome. Both preclinical and clinical studies suggest that GLP-1 RAs may provide neuroprotective benefits, including anti-apoptotic, anti-inflammatory, and cognitive-enhancing properties. These neuroprotective effects are supported by the molecular and pathophysiological pathways that could serve as potential targets for GLP-1 RAs.

Conclusion

GLP-1 RAs may offer neuroprotective benefits in patients with postoperative delirium and encephalopathies.. Cellular benefits involve pathophysiological or molecular pathways that are shared with other biological systems. While the current evidence is based on preclinical and clinical studies, more research involving human subjects is needed to clarify the role of GLP-1 RAs in various brain dysfunctions.